ERROR! No headcode.htm file found.


Clinical Focus

  • Breast Oncology
  • Medical Oncology

Academic Appointments

Professional Education

  • Board Certification: American Board of Internal Medicine, Medical Oncology (2019)
  • Fellowship: Yale Cancer Center (2019) CT
  • Residency: Georgetown University Medical Center (2016) DC
  • Medical Education: University of South Florida Morsani College of Medicine (2012) FL
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2015)

Research & Scholarship

Clinical Trials

  • An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic Recruiting

    This single arm, multicenter study provides the pertuzumab and trastuzumab fixed-dose combination formulation for subcutaneous injection (PH FDC SC) administered at home by a home health nursing provider for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer who have completed concurrent chemotherapy with pertuzumab (Perjeta) and trastuzumab (Herceptin) by intravenous administration (P+H IV) and are currently receiving or will be receiving maintenance therapy with P+H IV, PH FDC SC, or trastuzumab SC in the clinic. The main objective is to enable continuity of care during the COVID-19 pandemic. This study will enroll approximately 200 patients in the United States. Participants will receive treatment every 3 weeks and continue treatment unless early cessation is necessary due to disease recurrence, disease progression, unacceptable toxicity or participant withdrawal. Only participants with HER2+ early breast cancer will receive PH FDC SC to complete 18 cycles of dual blockade, including the P+H IV, PH FDC SC, or trastuzumab SC they received prior to enrolling in this study. A remote cardiac surveillance substudy will be optional for patients enrolled at the Mayo Clinic (select sites) and Memorial Sloan Kettering Cancer Center (MSKCC) sites. The Sponsor may decide to terminate the study when the COVID-19 pandemic is no longer a risk for this patient population.

    View full details

  • Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] Not Recruiting

    This study will compare DS-8201a to physician choice standard treatment. Participants must have HER2-low breast cancer that has been treated before. Participants' cancer: - Cannot be removed by an operation - Has spread to other parts of the body

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details


All Publications

  • Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO oncology practice Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., Adamson, B. J., Shaw, P., Parikh, R. B., Mamtani, R., Gross, C. P. 2020: OP2000010


    PURPOSE: As immune checkpoint inhibitors (ICIs) have transformed the care of patients with cancer, it is unclear whether treatment at the end of life (EOL) has changed. Because aggressive therapy at the EOL is associated with increased costs and patient distress, we explored the association between the Food and Drug Administration (FDA) approvals of ICIs and treatment patterns at the EOL.METHODS: We conducted a retrospective, observational study using patient-level data from a nationwide electronic health record-derived database. Patients had advanced melanoma, non-small-cell lung cancer (NSCLC; cancer types with an ICI indication), or microsatellite stable (MSS) colon cancer (a cancer type without an ICI indication) and died between 2013 and 2017. We calculated annual proportions of decedents who received systemic cancer therapy in the final 30 days of life, using logistic regression to model the association between the post-ICI FDA approval time and use of systemic therapy at the EOL, adjusting for patient characteristics. We assessed the use of chemotherapy or targeted/biologic therapies at the EOL, before and after FDA approval of ICIs using Pearson chi-square test.RESULTS: There was an increase in use of EOL systemic cancer therapy in the post-ICI approval period for both melanoma (33.9% to 43.2%; P < .001) and NSCLC (37.4% to 40.3%; P < .001), with no significant change in use of systemic therapy in MSS colon cancer. After FDA approval of ICIs, patients with NSCLC and melanoma had a decrease in the use of chemotherapy, with a concomitant increase in use of ICIs at the EOL.CONCLUSION: The adoption of ICIs was associated with a substantive increase in the use of systemic therapy at the EOL in melanoma and a smaller yet significant increase in NSCLC.

    View details for DOI 10.1200/OP.20.00010

    View details for PubMedID 32678688

  • Uptake of first-line immune checkpoint inhibitors among medically frail patients with advanced solid malignancies. Parikh, R., Cohen, R. B., Min, E., Wileyto, E., Riaz, F., Gross, C., Long, Q., Mamtani, R. LIPPINCOTT WILLIAMS & WILKINS. 2020
  • The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Riaz, F., Gan, G., Li, F., Davidoff, A. J., Adelson, K. B., Presley, C. J., Adamson, B. S., Shaw, P., Parikh, R., Mamtani, R., Gross, C. AMER SOC CLINICAL ONCOLOGY. 2020
  • Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer JOURNAL OF GERIATRIC ONCOLOGY Riaz, F., Presley, C. J., Chiang, A. C., Longtine, J. A., Soulos, P. R., Adelson, K. B., Herbst, R. S., Nussbaum, N. C., Sorg, R. A., Abernethy, A. P., Agarwala, V., Gross, C. P. 2019; 10 (4): 669?72

Stanford Medicine Resources: